Unimide® Syrup (generic name: Lacosamide) represents a highly effective therapeutic solution for controlling seizures in pediatric patients and individuals unable to swallow Unimide® tablets.

Unimide® Syrup is clinically indicated for the treatment and management of focal seizures in children over 1 month of age, either as monotherapy or adjunctive therapy. Furthermore, it is prescribed as an adjunctive treatment for generalized seizures in children aged 4 years and older. This innovative formulation can reduce the frequency of focal seizures by at least 50%, offering renewed hope for effective disease management.

Understanding Epilepsy

Disruptions in normal electrical brain activity lead to unpredictable and recurrent seizure episodes, a neurological condition known as epilepsy. A clinical diagnosis of epilepsy is established if an individual experiences two or more unprovoked seizures separated by a minimum of 24 hours. As a chronic condition and one of the most prevalent neurological disorders in childhood, selecting an appropriate, targeted antiepileptic medication is of paramount clinical importance.

Mechanism of Action and Clinical Efficacy

Due to its unique mechanism of action and optimal efficacy profile, Unimide® Syrup can be prescribed as both monotherapy and adjunctive therapy. In patients suffering from uncontrolled focal epilepsy who have a history of concurrent use of multiple other antiepileptic drugs (AEDs), this medication has demonstrated the ability to decrease focal seizure frequency by 50% or more.

Moreover, owing to its highly favorable, minimal drug-drug interaction profile, Unimide® Syrup facilitates enhanced, dual seizure control without necessitating complex alterations to the patient’s existing pharmacological regimen.

Cobel Darou’s Role in Neurology

Over the past two decades, Cobel Darou has been at the forefront of introducing innovative antiepileptic medications in the country. The company plays a pivotal role in the effective management of epilepsy, comprehensive patient education, and significantly improving the quality of life for Iranian patients.

Unimide® Syrup is developed by Cobel Darou and meticulously manufactured at Dr. Abidi Pharmaceuticals’ state-of-the-art facilities. It is fully approved by the Iran Food and Drug Administration (IFDA) and is currently available by prescription in pharmacies nationwide.

About Cobel Darou

For over 20 years, Cobel Darou has operated in close collaboration with, and under the license of, top-tier international pharmaceutical companies, focusing on the production, importation, and distribution of under-license medications. By ensuring a reliable, uninterrupted supply of essential therapeutics for Iranian patients—particularly specialty drugs—the company significantly contributes to elevating public health standards and enhancing individuals’ overall quality of life.

IR-1226-UNM-2779-PR